Table 1.
Baseline features of the IEI infected with SARS-CoV-2.
| IEI (n=25) | |
|---|---|
| Age (years) a | 14.3 (4.5-22.8) |
| Male | 15/25 (60.0%) |
| Caucasian | 20/25 (80.0%) |
| IEI | |
| Combined immunodeficiencies (CID) | 3/25 (12.0%) |
| CID with associated syndromic features | 12/25 (48.0%) |
| Predominantly antibody deficiencies | 4/25 (16.0%) |
| Diseases of immune dysregulation | 3/25 (12.0%) |
| Defects of phagocyte number, function, or both | 1/25 (4.0%) |
| Defects of intrinsic and innate immunity | 2/25 (8.0%) |
| Treatment | |
| Antibiotic, antiviral or antifungueal prophylaxis | 7/25 (28.0%) |
| IgRT | 6/25 (24.0%) |
| Immunomodulation therapy | 5/25 (20.0%) |
| Corticosteroids | 3/25 (12.0%) |
| Ruxolitinib | 1/25 (4.0%) |
| Dupilumab | 1/25 (4.0%) |
| COVID-19 severity | |
| Mild b | 21/25 (92.0%) |
| Moderate c | 3/25 (12.0%) |
| Severe | 1/25 (4.0%) |
| Clinical symptoms | 13/25 (52.0%) |
| Fever | 7/25 (28.0%) |
| Cough | 5/25 (20.0%) |
| Low-grade fever | 3/25 (12.0%) |
| Odynophagia | 3/25 (12.0%) |
| Runny nose | 2/25 (8.0%) |
| Asthenia | 2/25 (8.0%) |
| Smell and taste loss | 2/25 (8.0%) |
| Headache | 1/25 (4.0%) |
| Diarrhea | 1/25 (4.0%) |
| Myalgia | 1/25 (4.0%) |
| Ocular pain | 1/25 (4.0%) |
| Pneumonia | 4/25 (16.0%) |
| Hospitalization | 4/25 (16.0%) |
| COVID-19 treatement | 5/25 (20.0%) |
| Remdesivir | 4/25 (16.0%) |
| Corticosteroids | 2/25 (8.0%) |
| Antibiotic | 4/25 (16.0%) |
| Heparin | 1/25 (4.0%) |
| Conventional nasal prongs O2 | 1/25 (4.0%) |
| Comorbidities | |
| Respiratory disease | 5/25 (20.0%) |
| Cardiovascular disease | 3/25 (12.0%) |
| Neuropsychological disease | 8/25 (32.0%) |
| Obesity | 1/25 (4.0%) |
| Hemato-oncological disease | 1/25 (4.0%) |
a
Age and follow-up are expressed as median (min.-max.).
b
One mild case (asymptomatic, no pneumonia in the chest X-ray) was hospitalized because of the IEI risk (CID) and receive preventive remdesivir for 3 days.
c
One moderate case (non-hypoxemic pneumonia) did not require hospital care (P4).
CID, combined immunodeficiency; O2, oxygen; IEI, inborn error of immunity; IgRT, immunoglobulin replacement treatment.